Protein-protein interactions are widely found in biological systems controlling diverse cellular events. Because these interactions are implicated in many diseases such as autoimmunity and cancer, regulation of protein-protein interactions provides ideal targets for drug intervention. The CD80-CD28 costimulatory pathway plays a critical role in regulation of the immune response and thus constitutes an attractive target for therapeutic manipulation of autoimmune diseases. The objective of this study is to identify small compounds disrupting these pivotal protein-protein interactions. Compounds that specifically blocked binding of CD80 to CD28 were identified using a strategy involving a cell-based scintillation proximity assay as the initial step. Secondary screening (e.g., by analyzing the direct binding of these compounds to the target immobilized on a biosensor surface) revealed that these compounds are highly selective CD80 binders. Screening of structurally related derivatives led to the identification of the chemical features required for inhibition of the CD80-CD28 interaction. In addition, the optimization process led to a 10-fold increase in binding affinity of the CD80 inhibitors. Using this approach, the authors identify low-molecular-weight compounds that specifically and with high potency inhibit the interaction between CD80 and CD28. These compounds serve as promising starting points for further development of CD80 inhibitors as potential immunomodulatory drugs. (Journal of Biomolecular Screening 2007:464-472) FIG. 3. Results from follow-up screening of selected compounds using Biacore analysis. (A) Test of compounds for competition with binding of CD80 to immobilized CD28 and CTLA-4. Compounds at 50 µM were mixed with 20 µM CD80 prior to injection over the CD28 and the CTLA-4 surfaces in duplicate. (B) Direct binding of compounds 1 to 9 to immobilized CD80, CD28, and CD86. Compounds were injected at 40 µM in 5% DMSO. Data points represent reference-subtracted and DMSO-calibrated data of duplicate samples. (C) Sensorgrams showing direct binding of compound 9 to immobilized CD80 by injection at concentrations ranging from 25 nM to 10 µM. Spikes seen at the start and end of injections are due to a slight time delay in the reference cell and appear when reference subtraction is carried out. (D) Kinetic map of selected CD80 inhibitors with the association rate plotted versus the dissociation rate for each compound (number of compound indicated at each point). Note that optimization of compound 1 has generated more potent CD80-CD28 inhibitors, whereas the affinity for CD80 was increased because of a reduced off rate (compounds 6, 8, and 9) and a faster on rate (compounds 8 and 9). Compound identities in A through D are as described in Figure 2. 
INTRODUCTION
A S MORE INFORMATION on macromolecular structure and function unravels, it has become obvious that interprotein interactions are a ubiquitous and fundamental aspect of biological activity. The emergence of cell-surface receptors as viable drug targets, an idea first proposed more than 100 years ago by Paul Erlich, highlights the need for rapid, high-throughput screens for compounds that disrupt these interactions. 1 Even though the nature of protein-protein interactions is becoming better understood, rational approaches to inhibit these interactions are still in their infancy.
Because large protein surface areas of approximately 750 to 1500 Å 2 per protein are involved in interprotein interactions, blocking of such interactions with small molecules has been met with skepticism and regarded by the pharmaceutical industry as an almost impassable way to new drugs. 2 The pharmaceutical industry has tried to overcome this dilemma by developing protein drugs, the so-called biopharmaceuticals, such as monoclonal antibodies and soluble receptors toward cell surface receptors. 3 Several of these are marketed drugs, for example, soluble tumor necrosis factor-α (TNFα) receptor (Enbrel ® ), recombinant interleukin-2 (IL-2) (Proleukin ® ), and TNFα antibody (Remicade ® ). 4 However, a number of disadvantages are connected with the therapeutic use of biopharmaceuticals because, besides being costly to produce, they are immunogenic, exhibit poor bioavailability because of their size, and are prone to degradation. This causes stability problems and restrained dosing frequency and most often restricts administration to the intravenous route. In contrast, low-molecularweight drugs can be administered orally (per se or as prodrugs), daily dosing is allowed, and they are nonimmunogenic and metabolized, not degraded. 5 Despite the disbelief in the likelihood of success in the small-molecule approach, there are recent examples that prove the validity of the concept: inhibition of lymphocyte function-associated antigen-1 (LFA-1) binding to intracellular adhesion molecule-1 and IL-2 inhibitors. 2 These examples show that only a small portion of the overall intermolecular surface, the so-called hot spot, is critical for interactions with cell surface receptors. 6 The size of a typical hot spot is small enough to allow binding of low-molecularweight compounds to inhibit protein-protein interactions through binding to these important binding sites. 7 The mechanism behind the inhibitory effect could act on different molecular levels. For example, they could work as competitors of the natural ligand/receptor binding site or induce conformational changes leading to inhibition of protein-protein interactions. The discovery of small molecules as inhibitors of cell surface receptors is challenging, but if successful, it may open up a completely new field of novel therapeutics.
The past years have led to significant advances in the understanding of the critical role of immunoregulatory signals. These are delivered through the most prominent costimulatory pathway, namely, the CD28/B7 pathway involving the CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) receptors and their 2 ligands CD80 and CD86. 8 In this study, we have used the costimulatory pathway involving the CD80-CD28 interaction as target because it plays a key role in regulating T-cell activation and tolerance. Costimulatory signals are required to complete antigen-specific signaling through T-cell receptors (TCRs) upon recognition of major histocompatability complex (MHC) molecules loaded with peptide antigens. 9 In general, it is assumed that together with TCR signaling, engagement of CD28 leads to T-cell activation, whereas CTLA-4 engagement down-regulates T-cell activation. It is widely accepted that costimulation contributes to the maintenance of autoimmunity because of its function in activation of autoreactive T cells, differentiation, migration, and tolerance induction. 10 Although in vivo studies using antibodies and fusion proteins specific for costimulatory molecules as well as genetically manipulated animals have led to a more profound knowledge of how autoimmune responses are sustained through costimulation, the role of the costimulatory molecules is not completely understood. This is confirmed by conflicting results in the literature. 11 As an example, Windhagen and others showed that early-stage multiple sclerosis was accompanied by an up-regulation of costimulatory molecules such as CD80 and CD86. 12 Overexpression of CD80 has also been detected on B cells and monocytes in patients with rheumatoid arthritis. 13 It is still controversial whether, and to what extent, CD80 and CD86 provide qualitatively different signals to T lymphocytes, as the outcome of selective CD80 or CD86 blockade in vivo has been contradictory. Kuchroo and others, using experimental autoimmune encephalomyelitis (EAE) as a model of Th1-mediated disease, demonstrated that the selective CD80 blockade had a beneficial effect whereas blocking of CD86 worsened the disease. 14 By contrast, Lenchow and others, using the nonobese diabetic mouse model, showed the opposite. 15 Others have shown that blocking of CD80 and CD86 costimulation during the effector phase in an EAE model increased T cell apoptosis and attenuation of CNS inflammation. 16 Furthermore, CTLA4-Ig is used as an immunomodulator in a variety of clinical trails in, for example, rheumatoid arthritis, multiple sclerosis, and kidney transplantation. The results of these trials will provide proof of concept for the validity of the costimulatory pathway as a drug target. 17 Here we describe a successful strategy for identification and validation of small-molecule inhibitors of the costimulatory cell surface protein CD80 that serves as starting points in a drug discovery program. The 1st aim of the study was to identify low-molecular-weight compounds that can block the interaction between CD80 and CD28 by screening an in-house chemical library. A cell-based scintillation proximity assay (SPA), allowing multivalent presentation of CD28, was used for identification of compounds blocking the binding of CD80 to these cells. To sort out false positives, the same assay format was used to screen compounds for inhibition of anti-LFA-3 binding to LFA-3-expressing cells. LFA-3 was chosen as an appropriate negative control because it belongs to the same Ig family as CD28 and CTLA-4 and is known to mediate cell-cell adhesion through binding to the CD2 molecule on the T cell. 18 For further confirmation of specificity and binding affinities of hits, secondary screening was performed under cell-free conditions using homogeneous time-resolved fluorescence (HTRF) and biosensor approaches as inhibition and/or direct binding assays. Because of the high precision of our screening strategy, it was possible not only to identify potent and highly selective inhibitors of the CD80-CD28 interaction but also to obtain an extremely low number of false positives and a good correlation between cell-based and cell-free screening assays. Hence, in this study, we report the identification and characterization of low-molecularweight compounds that prevent CD80 from binding to its receptors, CD28 and CTLA-4. These results demonstrate that small antagonizing molecules may block protein-protein interactions taking place on cell surfaces and provide an excellent starting point for therapeutic intervention.
MATERIALS AND METHODS

Proteins and cells
Human CD80-murine Fab (CD80Fab), human CD28-murine Fc (CD28Fc), and human CTLA-4-human Fc (CTLA-4Fc) were produced as recombinant proteins by Pharmacia and Upjohn AB (Stockholm, Sweden). 19 His 6 -tagged human CD80 and CD86 were kindly supplied by Simon Davis (Oxford, UK). Human CD86-murine Fc (CD86Fc) was purchased from R&D Systems (Minneapolis, MN), biotin goat antimouse IgG from Southern-Biotech (Birmingham, AL), Eu-labeled antirabbit IgG from Wallac Oy (Turku, Finland), rabbit antimouse IgG from Jackson ImmunoResearch Labs Inc. (West Grove, PA), and LFA-3 monoclonal antibody from Biosource Int. (Nivelles, Belgium). The Chinese hamster ovary (CHO) cells used for transfection were purchased from ATCC (Rockville, MD). Transfectants
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were obtained as described, with protein expression verified by fluorescence-activated cell sorter analysis. 20
Primary screening assay
A cell-based SPA was used for primary screening. Compounds were tested for inhibition of the CD80-CD28 interaction, where CD80 was presented in a multivalent manner on SPA beads by capture through the Ig domain and CD28 was expressed on metabolically labeled CHO transfectant cells. To distinguish relevant from nonspecific binders, the same assay format was used with human LFA-3 expressed on CHO cells instead of CD28 and a monoclonal antibody raised against LFA-3 replacing CD80Fab for capture on the SPA beads. Validation of the primary screening assay was done by MDS Pharma Services USA (www.mdsps.com), formerly MDS Panlabs, using the Optiverse™ library. The assay was optimized for cell number and metabolic labeling conditions and validated for effects of DMSO and well-to-well and plate variability.
The parental and transfected CHO cells were grown and metabolically labeled as previously described. 19 The CHO cells were grown in RPMI 1640 with ultraglutamine supplemented with 10% v/v fetal calf serum, 100 µg/ml gentamycin, and 0.5 mg/ml hygromycin B as a selection agent for the CD28-CHO transfectants. For labeling the cells overnight, a leucine-free RPMI 1640 medium was used supplemented with 2 g/l D-glucose, 240 mg/l L-arginine, 35 mg/l inisitol, 15 mg/l methionine, 300 mg/l glutamine, 59.6 mg/l disodium cysteine, 2% v/v fetal calf serum, 0.5 mg/ml hygromycin B, and 150 µCi L-[4,5-3 H] leucine (Amersham Biosciences, Uppsala, Sweden) per million cells. Cells were incubated 18 to 20 h at 37 °C in a CO 2 incubator. Prior to use in the SPA, the CHO-CD28 cells were detached with a nonenzymatic cell dissociation solution and resuspended in assay buffer (see below) at a density of 10 5 cells per milliliter.
SPA polyvinyl toluene antimouse Ig beads (Amersham Biosciences) were diluted to 10 mg/ml in assay buffer, that is, Hanks' balanced salt solution without Ca 2+ and Mg 2+ containing 25 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES) and 1% bovine serum albumin. CD80Fab was added, gently mixed with the SPA beads at a concentration of 1.8 µg/ml beads, and incubated for 0.5 to 1.5 h at room temperature using end-over-end rotation.
Compounds screened were obtained from an in-house store as 2-mM stock solutions in DMSO and were diluted in assay buffer to give a final compound concentration of 180 µM and a DMSO concentration of 1% in the final assay. Metabolically labeled CHO-CD28 cells, 10 4 cells/100 µl, were added to each well in a white ISOplate-96 (Wallac Oy) with a clear bottom, followed by addition of the compound, diluted to a final concentration of 30 µM, and 25 µl CD80Fab-coated SPA beads. The plate was covered with a plastic lid, gently mixed on an orbital shaker for 1 min, and incubated at room temperature for 10 h. Plates were read in a Wallac TopCount using the SPA 3H High Quench Program with a count time of 1 min per well. To sort out nonspecific binders, compounds were tested in the irrelevant SPA for inhibition of 3 H-leucine-labeled CHO-LFA-3 cells to anti-hLFA-3 captured on SPA beads at a cell density of 2.5 × 10 3 cells and at an antibody concentration of 0.26 µg per well. Other conditions were as described for the relevant assay. Samples were run in duplicate.
HTRF
Hits selected from the primary screening were confirmed for specificity and potency in a cell-free HTRF assay. Compounds were analyzed for their ability to inhibit the interaction between CD80 and CD28 by preventing the distance-related energy transfer of excited Eu ions to the cross-linked allophycocyanin. CD80Fab and CD28Fc were captured by biotin goat antimouse IgG/streptavidin-allophycocyanin (Wallac Oy) and rabbit antimouse IgG/Eu-labeled antirabbit IgG (Wallac Oy) complexes, respectively. Half-area, black, 96-well, low-binding mircoplates (Costar; Life Technologies, Gaithersburg, MD) were used, and the resulting signal was measured in a Victor 2 1420 multiple reader (Wallac Oy) using the LANCE protocol. The HTRF experiments were performed mainly as described by Mellor and others. 21 CTLA-4 fused with a human Ig domain was used as a positive control in the assay. The final DMSO concentration was 0.5% in the HTRF assay because higher concentrations significantly decreased the signal.
Biacore competition assay
Compounds were further tested for inhibition of the interaction of CD80 or CD86 with CD28 and CTLA-4 using the Biacore 2000 system (Biacore AB, Uppsala, Sweden). CD28Fc and CTLA-4Fc were immobilized on separate flow cells on the same carboxymethylated dextran (CM5) chip using amine coupling. The competition assay was run in 10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20 called HBS-EP buffer (Biacore AB), at a final DMSO concentration of 1.5% and a flow rate of 10 µl/min. A 10-µl sample, consisting of 20 µM CD80His or CD86Fc in the absence or presence of a 50-µM compound, was injected over the flow cells containing immobilized CD28 and CTLA-4. After each injection, the chip was regenerated by injecting a 5-µl pulse of 5 mM NaOH.
Biacore direct binding assay
Direct binding of compounds to immobilized targets and kinetic evaluation of the resulting data were performed using the Biacore 3000 (Biacore AB). 22 Seven compounds were selected from previous screenings for binding verification to immobilized CD80His, CD28Fc, and CD86Fc. An unmodified dextran surface was used as a reference surface. The proteins were immobilized on a CM5 chip using the standard protocol for amine coupling. The immobilization levels were 5500, 10,000, and 8000 response units for CD80, CD86, and CD28, respectively, using 10 mM sodium acetate at pH 5.0 (CD80 and CD86) or at pH 4.5 (CD28) as immobilization buffer. The activity of the immobilized proteins was tested for binding to their natural ligands before and after screening by injecting CD28Fc, CTLA-4Fc, and CD80His over these surfaces and regeneration using 10 mM glycine-HCl, pH 3.
In a 1st set of experiments, the binding of compounds to the immobilized proteins was tested at 50 µM by injection in phosphate-buffered saline containing 5% v/v DMSO as running buffer. To compensate for the high bulk response produced by DMSO, calibration was done prior to the direct binding analysis according to the protocol elaborated by Biacore AB. True response values were then calculated using the correction factor obtained. A sample volume of 30 µl at a final compound concentration of 50 µM was injected at a flow rate of 30 µl/ml followed by washing with running buffer. Blank injections of running buffer were carried out regularly to check compound carryover from one cycle to another. Samples were run in duplicate.
Kinetic analysis was performed on a limited set of compounds as described above except that a broad concentration range (i.e., from 2.5 nM to 50 µM) was used. Reference and buffer subtracted data were fitted globally to a 1:1 interaction including a term of mass transfer using the BIAevaluation program 3.1 (Biacore AB).
Correlation calculation
The interassay correlation was tested using the Pearson correlation coefficient (SYSTAT, Statistical Solutions, Cork, Ireland).
RESULTS
Screening
The cell-based homogeneous SPA was used in the primary screening to identify compounds that inhibited the CD80-CD28 interaction. SPA is based on distance-related energy transfer to discriminate between bound and unbound ligand, and it is possible to configure the assay in both a cell-based (i.e., using metabolically labeled cells) and cell-free format. Considering that CD80 interacts with its counterreceptor with relatively low affinity, the primary screening was designed to facilitate a multivalent display of CD80 and CD28 to increase the avidity. The importance of permitting receptor clustering and multivalency to strengthen the interaction is further addressed by comparing the affinity obtained in our cell-based SPA, which was about 5 nM with the affinity obtained in the cell-free Biacore system, which is 4 µM (from Sørensen and others, and references therein 19 ). Moreover, fixation of cells before SPA analysis strongly reduced the CD80-CD28 binding (data not shown). It has also been shown that the natural engagement of CD80 and CD28 on antigen-presenting cells and T cells, respectively, occurs at clusters of TCR-MHC, adhesion and costimulatory molecules involved in the immunological synapses. 23 Applying a primary screening assay resembling this natural event was important to identify inhibitors that would be better adapted to function in this biological system. Although this assay cannot simulate the dynamics of ligand clustering in a membrane, it should, however, mimic clustering conditions via a spherical and high-density presentation of CD80. An irrelevant assay was run in parallel to exclude nonspecific binders.
Assay validation was performed by MDS Pharma Services (formerly MDS Panlabs) and showed that cell number did not significantly affect the half maximum binding concentration (EC 50 ) or the signal-to-noise ratio, which were 2.5 nM CD80 and 10:1, respectively, for the different cell numbers tested (2500 to 10,000 cells/well). The mean percentage of control in the assay variability test was 99.1% ± 15.6%. The variation between plates generated on the same or on different days produced coefficient of variation values of about 5% for both.
From a corporate compound library, diverse small-molecule compounds with druglike properties were selected. Steroids and presumably alkylating and cytotoxic compounds were excluded. A total of approximately 4000 compounds were tested in the primary screening, and hits were defined as those displaying more than 50% inhibition in the relevant assay and less than 20% inhibition in the irrelevant assay at a compound concentration of 30 µM. Only 1 compound that fulfilled these criteria was identified (here referred to as compound 1; see Fig. 1 ), yielding a hit rate of 0.03% in the primary screening. Subsequent screening of 29 structurally related compounds selected from the complete in-house library led to identification of 5 additional hits, of which the most potent are referred to as compounds 2 and 3 (Fig. 2) .
Based on the chemical structure of the most potent inhibitor selected in the primary screening, compound 1, a sublibrary consisting of approximately 150 analogous compounds was synthesized and screened for CD80 inhibition as mentioned above. Screening of this sublibrary in the SPA resulted in a couple of hits, which turned out to be significantly more potent than compound 1. A number of these analogs displayed an almost complete inhibition of the CD80-CD28 interaction at 30 µM, which is a significant improvement compared to the 61% inhibition obtained for compound 1 at the same concentration (Fig. 2) . Interestingly, all the hits from the sublibrary screening, compounds 6 to 9, have a p-benzoic acid substituent in the R1 position, indicating that this moiety is responsible for the increased potency of the analogs ( Table 1) . No false positives were identified in the primary screening assay.
Validation and characterization
Compounds selected in the primary screening were further examined in cell-free follow-up assays to eliminate false
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positives as well as to validate and characterize the targetinhibitor interaction.
In the 1st stage, the distance-related energy transfer-based HTRF assay was used to determine the inhibitory potency of the compounds in a quantitative manner. The most potent inhibitors (compounds 6 and 9) exhibited 3-to 5-fold lower IC 50 values than obtained for compound 1 (cf. Table 1 ). The positive control used in the HTRF assay, CTLA-4Fc, inhibited the CD80-CD28 interaction with an IC 50 value of 5 nM (data not shown), accounting for the 10-to 100-fold higher CD80-CTLA-4 affinity (see Sørensen and others and references therein 19 ). When Biacore analysis was used as a complementary way of determining inhibitory potency, the individual IC 50 values obtained were generally 10 times higher (data not shown). This may reflect to what extent the proteins are displayed in a monomeric (Biacore) or more multivalent (HTRF) way. However, although the absolute IC 50 values differed between the assays, the relation between the compounds remained the same, with compounds 6 and 9 as the most potent inhibitors (data not shown).
To elucidate whether the inhibition is due to an interaction of the compound with CD80 or CD28, binding experiments were performed using the surface plasmon resonance (SPR) technology. This technology allows measurement of biomolecular interactions in real time. In the 1st series of experiments, compound 1 was tested for competition with the binding of CD80 or CD86 to immobilized CD28 and CTLA-4. Compound 1 inhibited the binding of CD80 to both CD28 and CTLA-4 ( Fig.  3A) , indicating that it binds to an interaction site on CD80 shared by both CD28 and CTLA-4. As is shown in Figure 3A , this was also the case for the other compounds that inhibited the CD80-CD28 interaction. In contrast, the binding of CD86 to CD28 or CTLA-4 was not affected by any of the compounds tested (data not shown), which strongly suggests that these compounds are specific CD80 inhibitors.
In an attempt to prove that the compounds interact specifically with CD80, direct binding experiments were carried out using SPR technology, where the compounds were injected over a surface with immobilized CD80. This approach allowed detection of small molecules bound directly to the immobilized target despite the high bulk signals generated by DMSO in the sample and running buffers. Reference-subtracted and DMSO-calibrated data for 9 compounds tested at 40 µM for direct binding to immobilized CD80, CD28, and CD86 in different flow cells but on the same sensor chip are shown in Figure 3B . Three of these compounds (compounds 1-3) were selected as hits from the primary and structurally related compound screening, 4 (compounds 6-9) were hits from screening of the sublibrary, and the remaining 2 substances (compounds 4 and 5) were chosen as negative controls inasmuch as they exhibited no inhibition in the same assay. All compounds identified as hits by screening in the cell-based assay demonstrated distinct binding to immobilized CD80, whereas the 2 negative controls were weak binders (Fig.  3B) . As is also seen in Figure 3B , none of the CD80-CD28 inhibitors seemed to interact directly with immobilized CD86 or CD28. Hence, besides indicating an excellent precision in the primary screening assay as none of the compounds turned out to be false positives, these data provide strong evidence that these compounds act as CD80-CD28 inhibitors through a binding site exclusively situated on the CD80 molecule.
To further characterize the compound-CD80 interaction, we also investigated the kinetics for the binding of the compounds to immobilized CD80 by calculating the affinity and the association (k a ) and dissociation (k d ) rates from the SPR data. Six of the 7 CD80-CD28 inhibitors were analyzed in a wide concentration range (from 0.025 to 50 µM) with data fitted globally to a 1:1 binding model including a term of mass transfer, as this model best fitted our data according to the χ 2 value obtained. The resulting experimental sensorgrams for compound 9 are shown in Figure 3C , and in Figure 3D , the calculated association and dissociation rates for the 6 compounds are plotted in a k on /k off plot. Results are summarized in Table 1 and show that compound 9 has the highest affinity among the 5 analogs to compound 1 that were tested. The almost 10-fold higher affinity of compound 9 (compared to compound 1) is mainly due to a slower dissociation rate and, to a lesser extent, to an increased on rate (Fig. 3D) . These data, although restricted only to a small number of compounds, constitute a starting point for further optimization of CD80 inhibitors. Finally, to explore the correlation between data obtained in primary SPA and in the secondary HTRF and biosensor assays, Pearson's correlation coefficient was calculated. The correlation coefficients for SPA/HTRF, SPA/Biacore, and Biacore/HTRF assays were 0.83, 0.79, and -0.96, respectively. These are good correlations, taking into account that the assays go from a cellbased format allowing multivalent presentation of both receptor and ligand to cell-free assays with the same molecules present as soluble recombinant proteins.
DISCUSSION
Here we have described a strategy for identification of small-molecule inhibitors of cell surface receptors that are highly selective for CD80 (patented by Björk and others 24 ). The objective was to identify specific inhibitors of the CD80-CD28 costimulatory pathway among the ∼4000 compounds screened. For this purpose, the homogeneous cell-based assay used in the primary screening turned out to be excellently suited. The successful screening should be ascribed to the multivalent display of CD80 and CD28 on SPA beads and cells, respectively, strengthening the otherwise weak interaction and hence facilitating identification of potent inhibitors. Worth considering when analyzing the primary assay is the role of the costimulatory molecules in the T cell-antigen-presenting cell synapse formation, where blocking of signal 2 alters the morphology of the immunological synapse and reduces T-cell proliferation. 25 This adds another dimension to the primary screening assay, where not only compounds that inhibit single CD80-CD28 interactions are identified but also those that are capable of interrupting aggregated receptor-ligand complexes, a pivotal signaling event during T cell activation. 26 Much effort was put into the design of an irrelevant assay capable of sorting out false positives in a highly stringent way. The best format turned out to be the interaction between LFA-3 and a murine anti-LFA-3 antibody with LFA-3 overexpressed on 3 H-Leu-labeled CHO transfectants and the antibody captured on the same SPA beads as CD80Fab. Hence, compounds affecting receptor-ligand aggregation in a nonspecific manner could also be distinguished and excluded. The primary screening method described here has been thoroughly validated for use in high-throughput screening of large-compound libraries aiming at identification of CD80-CD28 inhibitors (data not shown).
The panel of methods used in this study, including both cellbased and cell-free assays and by detecting bound compound using an inhibition as well as a direct assay format, show an unusually stringent correlation that is important for identification and validation of hits with high precision and quality. Compounds identified as CD80-CD28 inhibitors in the 1st round and those tested in the subsequent optimization process all displayed CD80 specificity. Direct binding studies of these compounds using Biacore added very useful information on target specificity and kinetics of the compound-target interaction. The optimization process, involving the design and synthesis of structurally related derivatives and subsequent biochemical evaluation of these compounds, led to the discovery of CD80 inhibitors with significantly improved affinities (from 3 µM for compound 1 to less than 0.3 µM for compound 9). Although performed on a limited number of compounds, the valuable kinetic information provided by biosensor analysis formed the basis for an emerging structure-activity relation. The phenyl ring at position R1 is of vital importance for activity because replacement of this moiety (e.g., by cyclopentyl or tert-butyl groups) led to a complete loss of activity. A striking observation was that a -COOH substitution in the paraposition of the R1 phenyl group significantly improved the inhibitory potency of the derivatives. Substitutions in other positions (e.g., fluorine in position R3) seem to improve the interaction kinetics by affecting the association and/or the dissociation rates (see Table 1 ). Hence, the more detailed kinetic characterization provided by Biacore analysis served as a valuable tool for optimization of the drug-target interaction. As an affinity in the low nanomolar range is probably a requisite when considering desired properties of a potential drug candidate such as bioavailability, potency and toxicity, the best inhibitors described here, have to be improved. Further optimization and development of more potent CD80 inhibitors, based on the structure-activity data presented in this study, has recently been done, and the compound RhuDex ® has currently successfully passed a phase 1 clinical trial. 27 Interestingly, so far, we have identified only compounds that inhibit the CD80-CD28 interaction through binding to CD80. Although the most plausible explanation to this finding is the relatively few substances screened, it cannot be excluded that the orientation of the primary screening assay (i.e., with CD80 on the SPA beads and CD28 overexpressed on CHO cells) may skew the assay toward CD80 binders. When the reversed orientation of the primary SPA was tested, however, the number of false positives increased significantly (data not shown), probably because CD80-CHO cells were available only as transfectants coexpressing human HLA-DR4. 19 This study shows that small molecules can block costimulatory protein-protein interactions involving large surfaces. Interestingly, Erbe and others 28 have identified CD80 inhibitors that display structural similarities to our compounds. Using antibodies raised against CD80, they suggest that the binding site of their compounds is located near the proposed binding sites for CD28 and CTLA-4, at the GFCC′C″ face of the V-domain in CD80.
The interaction interface between CD80 and CTLA-4 has been determined to bury a total surface area of 1200 to 1300 Å 2 , and it exhibits a high degree of shape complementarity, being composed mostly of hydrophobic residues. 29 In contrast, the corresponding CD80-CD28 interface has been shown to involve weaker hydrophilic residues, which probably explain its lower affinity and also account for the stronger inhibition seen with our compounds in the latter interaction. 19, 30 A possible explanation for how the small molecules, which are approximately 10 Å in diameter, are able to interrupt such large areas might be that they bind to hot-spot residues and thereby prevent CD80 from binding to its receptors. Despite the fact that both CD80 and CD86 bind to the same receptors, an absolute CD80 specificity was demonstrated for our compounds, which could be explained by the relatively low sequence identity in the receptor-binding region of CD80 and CD86. By comparing the structures solved for the CD80-CTLA-4 and CD86-CTLA-4 complexes, only about 15% of the residues involved in CTLA-4 binding are identical in the 2 ligands. 29, 31 A more detailed understanding of the mechanism by which the CD80 inhibitors exert their inhibitory function is strongly motivated and may have important implications for elucidating the nature of the CD80-CD28 interaction.
Costimulation is a crucial pathway for immune responses, and it is likely that a blockade of this pathway has a potential in suppressing, for example, transplant graft rejection and autoimmune diseases. At present, several drugs and drug candidates for treatment of autoimmune diseases are targeting the cell surface receptors involved in the costimulatory pathway, but as they are all biopharmaceuticals, they therefore share the limitations of using macromolecular drugs in therapy such as immunogenicity, poor bioavailability, and stability. 32 This reinforces the need for small molecules as pharmaceuticals for the treatment of autoimmune diseases. The selective small-molecule CD80 inhibitors described in this study constitute excellent starting points for further preclinical and clinical development of drugs for treatment of autoimmune diseases.
